CNBC
French biotech stock soars 40% after new data on experimental medicine
Tuesday, June 30, 2026
Shares of French biotech company Abivax increased on Tuesday following the release of new data on its lead drug candidate for bowel disease. The company presented results from its clinical trials during a medical conference. Investors responded to the data release by trading the stock higher. The specific efficacy and safety findings were made public as part of the company's ongoing development program for the treatment.
Original reporting: https://www.cnbc.com/2026/06/30/abivax-stock-trial-data-biotech-obefazimod.html